Hollingsworth, national counsel for Novartis in litigation involving the osteoporosis drugs Aredia and Zometa, prevailed for its client twice this week. On Wednesday, a Second Circuit panel upheld the rejection of a pre-trial motion by the plaintiff in a Brooklyn case. The day before, a federal magistrate judge recommended that another case against Novartis in Rhode Island be dismissed.
Novartis Wins Twice in Suits over Osteoporosis Drugs with Assist from Hollingsworth
The Litigation Daily
August 30, 2012
This content is now available at LexisNexis®.
The ALM® and LexisNexis® Content Alliance
LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM’s legal news publications. LexisNexis® customers will be able to access and use ALM’s content by subscribing to the LexisNexis® services via lexis.com® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM’s other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.
ALM’s content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.
If you are not currently a LexisNexis subscriber, contact 1-800-227-4908 to find out more or click here to have a customer representative contact you directly.